Translational Development Acquisition Corp.(TDACW)Earnings, Financials & Key Ratios
TDACW•NASDAQ•Banking & Credit
$0.12
$558434 mkt cap·Price updated May 6, 2026
AboutTranslational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.Show more
- Net Interest Income$0
- Total Revenue$0
- Net Income-$71K+85.4%
- Return on Equity-0.08%
- Net Interest Margin0%
- ROA-0.08%+100.0%
- Equity / Assets96.43%+100.4%
- Book Value per Share19.54+31234.3%
- Tangible BV/Share19.54+31234.5%
TDACW Key Insights
Translational Development Acquisition Corp. (TDACW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Well capitalized: 96.4% equity/assets
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TDACW Price & Volume
Translational Development Acquisition Corp. (TDACW) stock price & volume — 10-year historical chart
Loading chart...
TDACW Growth Metrics
Translational Development Acquisition Corp. (TDACW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-55.13%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-217.79%
Return on Capital
10 Years-173.11%
5 Years-241.87%
3 Years-401.61%
Last Year-0.23%
TDACW Peer Comparison
Translational Development Acquisition Corp. (TDACW) competitors in SPACs and acquisition vehicles — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BRTX | 1.95M | 0.24 | -0.21 | 175.03% | -33.05% | -5.74% | ||
 HCAI | 16.69M | 15.43 | 10.33 | 19.45% | 5.48% | 0.42 | ||
 IQV | 29.95B | 176.47 | 22.51 | 5.87% | 8.33% | 22.11% | 2.44 | |
 CRL | 8.97B | 181.73 | -62.45 | -0.85% | -3.59% | -4.34% | 0.95 | |
 ICLR | 9.48B | 124.13 | 13.03 | 1.99% | 7.4% | 6.32% | 0.38 | |
 MEDP | 12.19B | 426.79 | 27.93 | 19.97% | 17.19% | 120.89% | 0.55 | |
 PRA | 1.27B | 24.60 | 24.85 | -2.67% | 6.04% | 4.95% | 0.32 | |
 BFLY | 1.19B | 4.55 | -14.68 | 18.96% | -73.63% | -36.79% | 0.10 |
Compare TDACW vs Peers
Translational Development Acquisition Corp. (TDACW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TDACW Income Statement
Translational Development Acquisition Corp. (TDACW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Net Interest Income | 0 | 0 | 0 | 348.43K | 0 | 0 | 0 | 0 |
| NII Growth % | - | - | - | - | -100% | - | - | 0% |
| Net Interest Margin % | 0% | 0% | 0% | 540.68% | 0% | 0% | 0% | 0% |
| Interest Income | 0 | 2.47M | 4.32M | 348.43K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 2.47M | 4.32M | 0 | 0 | 0 | 0 | 0 |
| Loan Loss Provision | 387 | -2.47M | -4.32M | 0 | 0 | 0 | 0 | 0 |
| Non-Interest Income | 0 | -2.47M | -4.32M | -348.43K | 0 | 0 | 0 | 0 |
| Non-Interest Income % | - | - | - | - | - | - | - | - |
| Total Revenue | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Revenue Growth % | - | - | - | - | - | - | - | 0% |
| Non-Interest Expense | 0 | -699.33K | -1.1M | -1.39M | 47.11K | 485.55K | 196.36K | 915.58K |
| Efficiency Ratio | - | - | - | - | - | - | - | - |
| Operating Income | -387▲ 0% | -699.33K▼ 180606.5% | -1.1M▼ 57.3% | -1.39M▼ 26.0% | -47.11K▲ 96.6% | -485.55K▼ 930.7% | -196.36K▲ 59.6% | -915.58K▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -180606.46% | -57.31% | -25.96% | 96.6% | -930.72% | 59.56% | - |
| Pretax Income | -387▲ 0% | 1.78M▲ 459719.6% | 3.22M▲ 81.2% | -1.03M▼ 131.8% | -47.11K▲ 95.4% | -485.55K▼ 930.7% | -71.01K▲ 85.4% | 4.76M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 374.64K | 690.82K | 217.09K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 21.06% | 21.43% | -21.16% | 0% | 0% | 0% | 0% |
| Net Income | -387▲ 0% | 1.4M▲ 362912.1% | 2.53M▲ 80.4% | -1.24M▼ 149.1% | -47.11K▲ 96.2% | -485.55K▼ 930.7% | -71.01K▲ 85.4% | 4.76M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | 362912.14% | 80.41% | -149.08% | 96.21% | -930.72% | 85.37% | -55.13% |
| Net Income (Continuing) | -387 | 1.4M | 2.53M | -1.24M | -47.11K | -485.55K | -71.01K | 4.76M |
| EPS (Diluted) | -0.00▲ 0% | 0.24▲ 240100.0% | 0.36▲ 50.0% | -0.17▼ 147.2% | -0.00▲ 98.5% | -0.06▼ 2300.0% | -3.31▼ 5416.7% | 0.28▲ 0% |
| EPS Growth % | - | - | 50% | -147.22% | 98.53% | - | -5416.67% | -217.79% |
| EPS (Basic) | -0.00 | 0.24 | 0.36 | -0.17 | -0.00 | -0.06 | -3.31 | - |
| Diluted Shares Outstanding | 5.76M | 5.76M | 7.1M | 7.18M | 19.05M | 8.09M | 8.64M | 17.25M |
TDACW Balance Sheet
Translational Development Acquisition Corp. (TDACW) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 143.4K | 1.26M | 74.43M | 64.38K | 2.23K | 2.02K | 438.17K | 727.18K |
| Cash & Due from Banks | 143.4K | 1.26M | 55.46K | 973 | 2.23K | 2.02K | 438.17K | 47.15K |
| Short Term Investments | 0 | 0 | 74.38M | 63.41K | 0 | 0 | 0 | 0 |
| Total Investments | 0 | 207.75M | 148.75M | 63.41K | 0 | 0 | 0 | 0 |
| Investments Growth % | - | - | -28.4% | -99.96% | -100% | - | - | 0% |
| Long-Term Investments | 0 | 207.75M | 74.38M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill & Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PP&E (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 404.24K | 1.2K | 1.2K | 63.41K | 383.01K | 0 | 174.35M | 179.9M |
| Total Current Assets | 143.4K | 1.32M | 158.38K | 1.04K | 54.23K | 2.02K | 650.23K | 80.58K |
| Total Non-Current Assets | 404.24K | 207.75M | 74.38M | 63.41K | 383.01K | 0 | 174.35M | 179.9M |
| Total Assets | 547.64K▲ 0% | 209.07M▲ 38077.1% | 74.54M▼ 64.3% | 64.44K▼ 99.9% | 437.24K▲ 578.5% | 2.02K▼ 99.5% | 175M▲ 8659008.3% | 179.98M▲ 0% |
| Asset Growth % | - | 38077.12% | -64.35% | -99.91% | 578.49% | -99.54% | 8659008.31% | 8948361.55% |
| Return on Assets (ROA) | -0.07% | 1.34% | 1.79% | -3.33% | -18.78% | -221.08% | -0.08% | 2.64% |
| Accounts Payable | 0 | 159.51K | 159.38K | 326 | 0 | 0 | 16.19K | 0 |
| Total Debt | 525K | 850K | 360K | 5.08M | 259K | 347.5K | 0 | 0 |
| Net Debt | 381.6K | -405.82K | 304.54K | -973 | 256.77K | 345.48K | -438.17K | -47.15K |
| Long-Term Debt | 0 | 425K | 180K | 0 | 0 | 0 | 0 | 0 |
| Short-Term Debt | 525K | 425K | 180K | 5.08M | 259K | 347.5K | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 6.04M | 6.04M |
| Total Current Liabilities | 525K | 958.31K | 1.02M | 5.4K | 459.39K | 509.68K | 210.3K | 422.85K |
| Total Non-Current Liabilities | 0 | 425.85K | 180K | 0 | 0 | 0 | 6.04M | 6.04M |
| Total Liabilities | 525K | 204.07M | 69.54M | 10.43K | 459.34K | 509.68K | 6.25M | 6.46M |
| Total Equity | 22.64K▲ 0% | 203.08M▲ 896832.8% | 68.49M▼ 66.3% | 54.23M▼ 20.8% | -22.11K▼ 100.0% | -507.66K▼ 2196.3% | 168.75M▲ 33341.4% | -6.38M▲ 0% |
| Equity Growth % | - | 896832.76% | -66.28% | -20.82% | -100.04% | -2196.26% | 33341.43% | 66164.75% |
| Equity / Assets (Capital Ratio) | 4.13% | 97.13% | 91.88% | 84150.81% | -5.06% | -25119.15% | 96.43% | -3.54% |
| Return on Equity (ROE) | -1.71% | 1.38% | 1.87% | -2.03% | -0.17% | - | -0.08% | 3.77% |
| Book Value per Share | 0.00 | 35.28 | 9.64 | 7.56 | -0.00 | -0.06 | 19.54 | -0.37 |
| Tangible BV per Share | 0.00 | 35.28 | 9.64 | 7.56 | -0.00 | -0.06 | 19.54 | -0.37 |
| Common Stock | 3.74K | 7.07K | 7.15K | 49.23K | 466 | 466 | 174.35M | 359.88M |
| Additional Paid-in Capital | 0 | 0 | 0 | 0 | 24.53K | 24.53K | 0 | 0 |
| Retained Earnings | -2.36K | 1.4M | 3.93M | 3.13K | -47.11K | -532.66K | -5.6M | -6.38M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TDACW Cash Flow Statement
Translational Development Acquisition Corp. (TDACW) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -387 | -603.66K | -1.53M | -1.85M | -97.16K | -204 | -851.45K | -851.45K |
| Operating CF Growth % | - | -155885.79% | -152.69% | -21.2% | 94.74% | 99.79% | -417275.49% | -2974.32% |
| Net Income | -387 | 1.4M | 2.53M | -1.24M | -47.11K | -485.55K | -71.01K | 4.76M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 851 | -851 | -217.09K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 381.6K | -2.75M | -2.84M | -1.24M | 0 | 482.34K | -120.63K | -6.7M |
| Working Capital Changes | -381.6K | 742.95K | -1.22M | 856.07K | -50.06K | 3.01K | -659.81K | -515.03K |
| Cash from Investing | 0 | -205.28M | 137.7M | 11.32M | 0 | 0 | -174.22M | -172.97M |
| Purchase of Investments | 0 | -205.28M | -500K | 0 | 0 | 0 | -174.22M | -174.22M |
| Sale/Maturity of Investments | 0 | 0 | 1000K | 0 | 0 | 0 | 0 | 0 |
| Net Investment Activity | 0 | -205.28M | 500K | 0 | 0 | 0 | -174.22M | -174.22M |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing | 0 | 0 | 0 | 11.32M | 0 | 0 | 0 | 1.26M |
| Cash from Financing | 87.83K | 206.99M | -137.38M | -8.55M | 99.39K | 0 | 175.51M | 174.65M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2M |
| Share Repurchases | 0 | 0 | -137.13M | -13.45M | 0 | 0 | 0 | 0 |
| Stock Issued | 0 | 207.73M | 0 | 0 | -125.61K | 0 | 169.05M | 169.05M |
| Net Stock Activity | 0 | 207.73M | -137.13M | -13.45M | -125.61K | 0 | 169.05M | 169.05M |
| Debt Issuance (Net) | 0 | 0 | 0 | 0 | 225K | 0 | -393.46K | -663.46K |
| Other Financing | 87.83K | 206.99M | -137.38M | -8.55M | 0 | 0 | 6.86M | 8.27M |
| Net Change in Cash | 87.45K▲ 0% | 1.11M▲ 1172.1% | -1.2M▼ 207.9% | 917.33K▲ 176.4% | 2.23K▼ 99.8% | -204▼ 109.2% | 436.15K▲ 213900.5% | -176.89K▲ 0% |
| Exchange Rate Effect | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -28.72K |
| Cash at Beginning | 55.95K | 143.4K | 1.26M | 55.46K | 0 | 2.23K | 2.02K | 35.26K |
| Cash at End | 143.4K | 1.26M | 55.46K | 972.79K | 2.23K | 2.02K | 438.17K | 47.15K |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -387▲ 0% | -603.66K▼ 155885.8% | -1.53M▼ 152.7% | -1.85M▼ 21.2% | -97.16K▲ 94.7% | -204▲ 99.8% | -851.45K▼ 417275.5% | -2.46M▲ 0% |
| FCF Growth % | - | -155885.79% | -152.69% | -21.2% | 94.74% | 99.79% | -417275.49% | -105.05% |
TDACW Banking Ratios
Translational Development Acquisition Corp. (TDACW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 1.38% | 1.87% | -2.03% | -0.17% | - | -0.08% | 3.77% |
| Return on Assets (ROA) | 1.34% | 1.79% | -3.33% | -18.78% | -221.08% | -0.08% | 2.64% |
| Net Interest Margin | 0% | 0% | 540.68% | 0% | 0% | 0% | 0% |
| Equity / Assets | 97.13% | 91.88% | 84150.81% | -5.06% | -25119.15% | 96.43% | -3.54% |
| Book Value / Share | 35.28 | 9.64 | 7.56 | -0 | -0.06 | 19.54 | -0.37 |
| NII Growth | - | - | - | -100% | - | - | 100% |
| Dividend Payout | - | - | - | - | - | - | 2.63% |
TDACW Frequently Asked Questions
Translational Development Acquisition Corp. (TDACW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Translational Development Acquisition Corp. (TDACW) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Translational Development Acquisition Corp. (TDACW) is profitable, generating $4.8M in net income for fiscal year 2024.
Dividend & Returns
Translational Development Acquisition Corp. (TDACW) has a return on equity (ROE) of -0.1%. Negative ROE indicates the company is unprofitable.
Industry Metrics
Translational Development Acquisition Corp. (TDACW) has a net interest margin (NIM) of N/A. NIM has been under pressure due to interest rate environment.
Translational Development Acquisition Corp. (TDACW) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.
Explore More TDACW
Translational Development Acquisition Corp. (TDACW) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates